Global Apheresis Market - Forecasts from 2020 to 2025
The global apheresis market is estimated to augment at a CAGR of 7.97% to reach a market size of US$1,578.700 million in 2025 from US$996.509 million in 2019. The global apheresis market is projected to flourish in the forecast period with the growing prevalence of chronic diseases, and the increasing number of severe injury and trauma cases. The growing demand for blood components like RBCs, WBCs, and platelets are further fueling the market demand in the forecast period. With the rise in blood donation programs creating awareness to promote voluntary blood donation is further providing an opportunity in strengthening the market growth at a significant pace during the upcoming years. Additionally, the increasing number of complex surgeries requiring blood components or apheresis for treatment purposes is propelling the market growth in the forecast period. Furthermore, the prevalence of blood disorders at the global level is also driving the market demand in the forecast period.
Geographically, North America is accounted to hold a significant market share in the global apheresis market owing to the early technology adoption and the presence of advanced medical facilities with specialized treatment procedures and equipment. The Asia Pacific region, on the other hand, is estimated to experience high growth with the growing government initiatives for blood donation, in addition, investments in providing better healthcare facilities are estimated to propel the market growth in the forecast period and in the upcoming years.
The presence of blood donation programs is fueling the growth of the global apheresis market with the increased need for the installation of apheresis equipment for safe blood donation.
Republic of Philippines, Department of Health, blood donation program is in accordance with the Republic Act No. 7719, which is also known as the National Blood Services Act of 1994. This is promoting the individuals for voluntary blood donation offering sufficient supply of safe blood, in addition to regulating blood banks. This act further is focused on inculcating public awareness that blood donation is a humanitarian act. The National Voluntary Blood Services Program of the Department of Health is aimed towards targeting youth as volunteers for blood donation program. Also, this aims towards creating awareness regarding the importance of blood donation in saving millions of lives of the people in the Philippines. On the basis of its continuous efforts, the Department of Health in the Philippines hopes that this will encourage many individuals to vote for voluntary unpaid blood donation and ensure the supply of safe blood in order to meet the blood necessities in the country.
The Indian Red Cross is a voluntary humanitarian organization in India with more than 1100 branches across the nation. The organization’s mission is to inspire, encourage, and initiate all the forms of humanitarian activities in order to reduce human suffering, further contributing to creating peace. The organization is a leader in the field of blood services and is one of the largest voluntary blood banks in India since 1962. The IRCS, Indian Red Cross Society is responsible for the conduction of motivational campaigns on a regular basis and organizes Voluntary Blood Donation Camps. It comprises over 100 blood banks throughout the country. The organization’s National Headquarters blood bank is focused on motivating people for voluntary blood donation and collects around 25000 units of blood every year. The percentage of voluntary blood donation is more than 90% in IRCS in comparison to more than 20% of the blood collection by the other blood banks in Delhi. Additionally, the blood bank provides around 90% of the total blood collected free of service charge to the patients admitted in the General ward of Govt. hospitals in Delhi. Also, the blood is supplied to the 975 Thalassemic patients registered with these hospitals comprising around 50% of all the patients suffering from thalassemia in Delhi.
Companies offering apheresis systems are further providing an opportunity for the market to grow in the forecast period.
Mallinckrodt company’s Therakos therapeutic platforms offer the latest generation THERAKOS®CELLEX® Photopheresis System. This is the world’s only approved, fully-integrated system for the administration of autologous immune cell therapy via extracorporeal photopheresis. The system is in high demand among the academic medical centers, hospitals, and treatment centers in over 30 countries, in addition to delivering more than one million treatments at the global level. The photopheresis system is used in the palliative treatment of skin manifestations of Cutaneous T-Cell Lymphoma that is not responsive to the other forms of treatment available. The apheresis system combines the advanced cell collection, photoactivation, and reinfusion technologies, all in one single, integrated, closed system. This allows for single operator management of the photopheresis process and is intended for reducing the risks of infections, cross-contamination, and patient reinfusion errors.
Also, the machine is capable of reducing treatment time in half, a great invention. The features of the CELLEX® system include advanced, single-harvest centrifuge design with continuous separation, flexible treatment options which include customized fluid management and single or double needle mode for varying needs of the patient, also, the double needle mode is responsible for the reduction of treatment time to half. The patented algorithm is useful in automating cell collection and optimizing UVA activation of the cell product. The provision of the single-use sterile procedural kit helps in easy set up and minimal waste. The system consists of highly visible, multilingual interactive display for enhancing ease in operation and training. The presence of automated sensors and flow rate is helpful in optimization of collection photoactivation time. Other automated safety features include air emboli detector, audible alarms, and message display for specific alarm status, and line occlusion of all the fluid lines.
B. Braun Melsungen AG’s apheresis machine, Plasmat Futura is designed for performing H.E.L.P apheresis (heparin-induced extracorporeal LDL precipitation). This is utilized for extracorporeal elimination of LDL cholesterol in patients having a family history of hypercholesterolemia, hyperlipoproteinemia, hyperfibrinogenemia, and transplant vasculopathy. The procedure involves the purification of blood where the plasma is initially separated from the blood cells. By the addition of acetate buffer for acidification and heparin to the plasma LDL cholesterol, fibrinogen and lipoprotein (a) is precipitated. The precipitate is finally removed through filtration and the excess of heparin is removed by the specific adsorption from the blood plasma. In the end, the bicarbonate dialysis the initial volume and the physiologic pH value of the processed plasma are reconstituted.
Segmentation:
Geographically, North America is accounted to hold a significant market share in the global apheresis market owing to the early technology adoption and the presence of advanced medical facilities with specialized treatment procedures and equipment. The Asia Pacific region, on the other hand, is estimated to experience high growth with the growing government initiatives for blood donation, in addition, investments in providing better healthcare facilities are estimated to propel the market growth in the forecast period and in the upcoming years.
The presence of blood donation programs is fueling the growth of the global apheresis market with the increased need for the installation of apheresis equipment for safe blood donation.
Republic of Philippines, Department of Health, blood donation program is in accordance with the Republic Act No. 7719, which is also known as the National Blood Services Act of 1994. This is promoting the individuals for voluntary blood donation offering sufficient supply of safe blood, in addition to regulating blood banks. This act further is focused on inculcating public awareness that blood donation is a humanitarian act. The National Voluntary Blood Services Program of the Department of Health is aimed towards targeting youth as volunteers for blood donation program. Also, this aims towards creating awareness regarding the importance of blood donation in saving millions of lives of the people in the Philippines. On the basis of its continuous efforts, the Department of Health in the Philippines hopes that this will encourage many individuals to vote for voluntary unpaid blood donation and ensure the supply of safe blood in order to meet the blood necessities in the country.
The Indian Red Cross is a voluntary humanitarian organization in India with more than 1100 branches across the nation. The organization’s mission is to inspire, encourage, and initiate all the forms of humanitarian activities in order to reduce human suffering, further contributing to creating peace. The organization is a leader in the field of blood services and is one of the largest voluntary blood banks in India since 1962. The IRCS, Indian Red Cross Society is responsible for the conduction of motivational campaigns on a regular basis and organizes Voluntary Blood Donation Camps. It comprises over 100 blood banks throughout the country. The organization’s National Headquarters blood bank is focused on motivating people for voluntary blood donation and collects around 25000 units of blood every year. The percentage of voluntary blood donation is more than 90% in IRCS in comparison to more than 20% of the blood collection by the other blood banks in Delhi. Additionally, the blood bank provides around 90% of the total blood collected free of service charge to the patients admitted in the General ward of Govt. hospitals in Delhi. Also, the blood is supplied to the 975 Thalassemic patients registered with these hospitals comprising around 50% of all the patients suffering from thalassemia in Delhi.
Companies offering apheresis systems are further providing an opportunity for the market to grow in the forecast period.
Mallinckrodt company’s Therakos therapeutic platforms offer the latest generation THERAKOS®CELLEX® Photopheresis System. This is the world’s only approved, fully-integrated system for the administration of autologous immune cell therapy via extracorporeal photopheresis. The system is in high demand among the academic medical centers, hospitals, and treatment centers in over 30 countries, in addition to delivering more than one million treatments at the global level. The photopheresis system is used in the palliative treatment of skin manifestations of Cutaneous T-Cell Lymphoma that is not responsive to the other forms of treatment available. The apheresis system combines the advanced cell collection, photoactivation, and reinfusion technologies, all in one single, integrated, closed system. This allows for single operator management of the photopheresis process and is intended for reducing the risks of infections, cross-contamination, and patient reinfusion errors.
Also, the machine is capable of reducing treatment time in half, a great invention. The features of the CELLEX® system include advanced, single-harvest centrifuge design with continuous separation, flexible treatment options which include customized fluid management and single or double needle mode for varying needs of the patient, also, the double needle mode is responsible for the reduction of treatment time to half. The patented algorithm is useful in automating cell collection and optimizing UVA activation of the cell product. The provision of the single-use sterile procedural kit helps in easy set up and minimal waste. The system consists of highly visible, multilingual interactive display for enhancing ease in operation and training. The presence of automated sensors and flow rate is helpful in optimization of collection photoactivation time. Other automated safety features include air emboli detector, audible alarms, and message display for specific alarm status, and line occlusion of all the fluid lines.
B. Braun Melsungen AG’s apheresis machine, Plasmat Futura is designed for performing H.E.L.P apheresis (heparin-induced extracorporeal LDL precipitation). This is utilized for extracorporeal elimination of LDL cholesterol in patients having a family history of hypercholesterolemia, hyperlipoproteinemia, hyperfibrinogenemia, and transplant vasculopathy. The procedure involves the purification of blood where the plasma is initially separated from the blood cells. By the addition of acetate buffer for acidification and heparin to the plasma LDL cholesterol, fibrinogen and lipoprotein (a) is precipitated. The precipitate is finally removed through filtration and the excess of heparin is removed by the specific adsorption from the blood plasma. In the end, the bicarbonate dialysis the initial volume and the physiologic pH value of the processed plasma are reconstituted.
Segmentation:
- By Product
- Centrifugal Apheresis Devices
- Membrane Apheresis Devices
- Apheresis Disposables
- By Procedure
- Automated Blood Collection
- Therapeutic Apheresis
- By Technology
- Centrifugation
- Membrane Filtration
- By Application
- Plasmapheresis
- Photopheresis
- Others
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- France
- Others
- Middle East and Africa
- UAE
- Israel
- Saudi Arabia
- Others
- Asia Pacific
- Japan
- China
- India
- Australia
- Others
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. GLOBAL APHERESIS MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Centrifugal Apheresis Devices
5.3. Membrane Filtration Apheresis Devices
5.4. Apheresis Disposables
6. GLOBAL APHERESIS MARKET ANALYSIS, BY PROCEDURE
6.1. Introduction
6.2. Automated Blood Collection
6.3. Therapeutic Apheresis
7. GLOBAL APHERESIS MARKET ANALYSIS, BY TECHNOLOGY
7.1. Introduction
7.2. Centrifugation
7.3. Membrane Filtration
8. GLOBAL APHERESIS MARKET ANALYSIS, BY APPLICATION
8.1. Introduction
8.2. Plasmapheresis
8.3. Photopheresis
8.4. Others
9. GLOBAL APHERESIS MARKET ANALYSIS, BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. North America Apheresis Market, By Product
9.2.2. North America Apheresis Market, By Procedure
9.2.3. North America Apheresis Market, By Technology
9.2.4. North America Apheresis Market, By Therapeutic Application
9.2.5. By Country
9.2.5.1. United States
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. South America Apheresis Market, By Product
9.3.2. South America Apheresis Market, By Procedure
9.3.3. South America Apheresis Market, By Technology
9.3.4. South America Apheresis Market, By Therapeutic Application
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Others
9.4. Europe
9.4.1. Europe Apheresis Market, By Product
9.4.2. Europe Apheresis Market, By Procedure
9.4.3. Europe Apheresis Market, By Technology
9.4.4. Europe Apheresis Market, By Therapeutic Application
9.4.5. By Country
9.4.5.1. UK
9.4.5.2. Germany
9.4.5.3. France
9.4.5.4. Others
9.5. Middle East and Africa
9.5.1. Middle East and Africa Apheresis Market, By Product
9.5.2. Middle East and Africa Apheresis Market, By Procedure
9.5.3. Middle East and Africa Apheresis Market, By Technology
9.5.4. Middle East and Africa Apheresis Market, By Therapeutic Application
9.5.5. By Country
9.5.5.1. United Arab Emirates
9.5.5.2. Israel
9.5.5.3. Saudi Arabia
9.5.5.4. Others
9.6. Asia Pacific
9.6.1. Asia Pacific Apheresis Market, By Product
9.6.2. Asia Pacific Apheresis Market, By Procedure
9.6.3. Asia Pacific Apheresis Market, By Technology
9.6.4. Asia Pacific Apheresis Market, By Therapeutic Application
9.6.5. By Country
9.6.5.1. Japan
9.6.5.2. China
9.6.5.3. India
9.6.5.4. Australia
9.6.5.5. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix
11. COMPANY PROFILES
11.1. TERUMO BCT, INC.
11.2. Fresenius Medical Care AG & Co. KGaA
11.3. Haemonetics Corporation
11.4. Baxter International, Inc.
11.5. Asahi Kasei Medical Co., Ltd.
11.6. B. Braun Melsungen AG
11.7. Kaneka Corporation
11.8. Macopharma
11.9. Miltenyi Biotec
11.10. Mallinckrodt
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Market Opportunities
4.4. Porters Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Competitive Rivalry in the Industry
4.5. Industry Value Chain Analysis
5. GLOBAL APHERESIS MARKET ANALYSIS, BY PRODUCT
5.1. Introduction
5.2. Centrifugal Apheresis Devices
5.3. Membrane Filtration Apheresis Devices
5.4. Apheresis Disposables
6. GLOBAL APHERESIS MARKET ANALYSIS, BY PROCEDURE
6.1. Introduction
6.2. Automated Blood Collection
6.3. Therapeutic Apheresis
7. GLOBAL APHERESIS MARKET ANALYSIS, BY TECHNOLOGY
7.1. Introduction
7.2. Centrifugation
7.3. Membrane Filtration
8. GLOBAL APHERESIS MARKET ANALYSIS, BY APPLICATION
8.1. Introduction
8.2. Plasmapheresis
8.3. Photopheresis
8.4. Others
9. GLOBAL APHERESIS MARKET ANALYSIS, BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. North America Apheresis Market, By Product
9.2.2. North America Apheresis Market, By Procedure
9.2.3. North America Apheresis Market, By Technology
9.2.4. North America Apheresis Market, By Therapeutic Application
9.2.5. By Country
9.2.5.1. United States
9.2.5.2. Canada
9.2.5.3. Mexico
9.3. South America
9.3.1. South America Apheresis Market, By Product
9.3.2. South America Apheresis Market, By Procedure
9.3.3. South America Apheresis Market, By Technology
9.3.4. South America Apheresis Market, By Therapeutic Application
9.3.5. By Country
9.3.5.1. Brazil
9.3.5.2. Argentina
9.3.5.3. Others
9.4. Europe
9.4.1. Europe Apheresis Market, By Product
9.4.2. Europe Apheresis Market, By Procedure
9.4.3. Europe Apheresis Market, By Technology
9.4.4. Europe Apheresis Market, By Therapeutic Application
9.4.5. By Country
9.4.5.1. UK
9.4.5.2. Germany
9.4.5.3. France
9.4.5.4. Others
9.5. Middle East and Africa
9.5.1. Middle East and Africa Apheresis Market, By Product
9.5.2. Middle East and Africa Apheresis Market, By Procedure
9.5.3. Middle East and Africa Apheresis Market, By Technology
9.5.4. Middle East and Africa Apheresis Market, By Therapeutic Application
9.5.5. By Country
9.5.5.1. United Arab Emirates
9.5.5.2. Israel
9.5.5.3. Saudi Arabia
9.5.5.4. Others
9.6. Asia Pacific
9.6.1. Asia Pacific Apheresis Market, By Product
9.6.2. Asia Pacific Apheresis Market, By Procedure
9.6.3. Asia Pacific Apheresis Market, By Technology
9.6.4. Asia Pacific Apheresis Market, By Therapeutic Application
9.6.5. By Country
9.6.5.1. Japan
9.6.5.2. China
9.6.5.3. India
9.6.5.4. Australia
9.6.5.5. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix
11. COMPANY PROFILES
11.1. TERUMO BCT, INC.
11.2. Fresenius Medical Care AG & Co. KGaA
11.3. Haemonetics Corporation
11.4. Baxter International, Inc.
11.5. Asahi Kasei Medical Co., Ltd.
11.6. B. Braun Melsungen AG
11.7. Kaneka Corporation
11.8. Macopharma
11.9. Miltenyi Biotec
11.10. Mallinckrodt
